Metabolic syndrome: From insulin resistance to adipose tissue dysfunction;Sindrome metabolica: Dall'insulino-resistenza alla disfunzione del tessuto adiposo

Minerva Medica

Volumn 99, Issue 3, 2008, Pages 307-321

  Camera, A ^a   Hopps, E ^a   Caimi, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Adipokines; Adipose tissue; Cytokines; Metabolic syndrome X

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; CYTOKINE; INSULIN; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETINOL BINDING PROTEIN 4; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DIABETES MELLITUS; ECTOPIC FAT STORAGE SYNDROME; FATALITY; GLUCONEOGENESIS; HEART MUSCLE ISCHEMIA; HUMAN; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIPID STORAGE; LIPID TRANSPORT; LIPODYSTROPHY; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADIPONECTIN; ADIPOSE TISSUE; C-REACTIVE PROTEIN; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INTERLEUKIN-6; LEPTIN; METABOLIC SYNDROME X; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETINOBLASTOMA PROTEIN; TERMINOLOGY AS TOPIC;

EID: 46449136098     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Kahn R. Metabolic Syndrome: Is It a Syndrome? Does It Matter? Circulation 2007;115:1806-11.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
3. Federspil G, Nisoli E, Vettor R. A critical reflection on the definition of metabolic sindrome. Pharmacol Res 2006;53:449-56.
4. Reilly MP, Rader DJ. The metabolic syndrome. More than the sum of its parts? Circulation 2003;108:1546-51.
5. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005;51:931-8.
6. Penno G, Miccoli R, Pucci L, Del Prato S. The metabolic syndrome. Beyond the insulin resistance syndrome. Pharmacol Res 2006;53:457-68.
7. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-9.
8. Grundy SM, Breswer HB, Cleeman JL, Smith SC, Lenfant C. American Heart Association; National Heart Lung and Blood Institute. Definition of Metabolic Syndrome: Report of the National Heart, Lung And Bloodinstitute/American Hart Association Conference On Scientific Issues Related To Definition. Circulation 2004;109:433-8.
9. Kahn R, Buse J, Ferranini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005;28:2289-304.
10. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.
11. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-72.
12. Vasseur F. Adiponectin and its receptors: partners contributing to the "vicious circle" leading to the metabolic syndrome? Pharmacol Res 2006;53:478-81.
13. Stern MP, Hunt KJ, Williams K, Haffner SM, Gonzalez-Villalpando C. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-81.
14. Stern MP, Williams K, Hunt KJ. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler 2005;6(Suppl):3-6.
15. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and all causes in United States Adults. Circulation 2004;110:1245-50.
16. Jazet IM, Pijl H, Meinders AE. Adipose tissue as an endocrine organ: impact on insulin resistane. Neth J Med 2003;61:194-212.
17. Laclaustra M, Corella D, Ordova JM. Metabolic sindrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis 2007;17:125-39-
18. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A et al. Plasma leptin and risk of cardiovascular disease in the West of Scotland Coronary prevention Study (WOSCOPS). Circulation 2003;104:3052-6.
19. Shamsuzzaman ASM, Winnicki M, Wolk R, Svatikova A, Philips BG, Davison DE et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 2004;109:2181-5.
20. Dandona P, Aijada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.
21. Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998;26:398-401.
22. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007;356:237-47.
23. Sader S, Nian M, Liu P. Leptin. A novel link between obesity, diabetes, cardiovascular risk and ventricular hypertrophy. Circulation 2003;108:644-6.
24. Barouch LA, Berkovitz DE, Harrison RW, O'Donnel CP, Hare JM. Disruption of leptin signalling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003;108:754-9.
25. Mc Crindle BW, Urbina EM, Dennison BA, Jacobson MS, Stenberg J, Rocchini AP. Drugs therapy of high-risk lipid abnormalities in children and adolescents. Circulation 2007;115:1948-67.
26. Eldor R, Raz I. Lipotoxicity versus adipotoxicity - the deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes. Diabetes Res Clin Pract 2006;74:S3-S8.
27. Nisoli E, Carruba MO. Tessuto adiposo bruno e insulino-resistenza: fattori metabolici e possibili meccanismi. Diabete 1998;35-46.
28. Ferranini E. Sindrome metabolica: dalla medicina molecolare alla medicina clinica. Epidemiologia. Ann Ital Med Int 2005;20:44S-56S.
29. Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K et al. Association of low adiponectina levels with the metabolic syndrome- the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 2005;54:476-81.
30. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A et al. Adiponectin replenishment ameliorates obesità-related hypertension. Hypertension 2006;47:1108.
31. Gable DR, Hurel SJ, Humpries SE. Adiponectin and its gene variants as risk factors for insulin-resistance, the metabolic syndrome and cardiovascular disease. Atherosclerosis 2006;188:231-44.
32. Salmenniemi U, Routsalainen E, Philajamaki J, Vauhkonen I, Kainulainen S, Punnonen K et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectina, cytokines and adhesion molecules in subjects with the metabolic syndrome. Circulation 2004;110:3842-8.
33. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M et al. Reciprocal association of C-reactive protein with adiponectina in blood stream and adipose tissue. Circulation 2003;107:671-4.
34. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW. C-reactive protein, the metabolic syndrome and prediction of cardiovascular events in the Framingham offspring study. Circulation 2004;110:380-5.
35. Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006;71:92-100.
36. González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 2006;60:802-9.
37. Bo S, Gambino R, Uberti B, Mangiameli MP, Colosso G, Repetti E et al. Does C-reactive protein identify a subclinical metabolic disease in healthy subjects? Eur J Clin Invest 2005;35:265-70.
38. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002;106:2908-12.
39. Chandalia M, Cabo-Chan AV Jr, Devaraj S, Jialal I, Grundy SM, Abate N. Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab 2003;88:3773-6.
40. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner S. Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 2000;102:42-7.
41. Ferraz TB, Motta RS, Ferraz CL, Capibaribe DM, Forti AC, Chacra AR. C-reactive protein and features of metabolic syndrome in Brazilian women with previous gestational diabetes. Diabetes Res Clin Pract 2007;78:23-9.
42. Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
43. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97:3A-11A.
44. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439-41.
45. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Circulation 2003;107:398-404.
46. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003;108:420-5.
47. Festa A, D'Agostino R, Rich SS, Jenny NS, Tracy RP, Haffner S. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics and non-hispanics whites. Circulation 2003;107:2422-7.
48. Juahn Vogue I, Alessi MC. PAI-1 and atheromrombosis. Thromb Hemost 1993;70:138-53.
49. Lopez-Aemany R, Redondo JM, Nagamine Y, Munoz-Canoves P. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 2003;270:814-21.
50. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Trhomb Vasc Biol 2000;20:1150-4.
51. Ma LJ, Mao SL, Taylor KL, Kanjabuch T, Guan YF, Zhang YH et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53:336-46.
52. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome. A comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 2005;111:1448-54.
53. Nordt TK, Kornas K, Peter K, Fujii S, Sobel BE, Kubier W et al. Attenuation by gemfibrozil of expresson of plasminogen activator inhibitor type 1 induced by insulin and its precursors. Circulation 1997;95:677-83.
54. Shafer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 2001;15:1840-2.
55. Stephens RH, McElduff P, Heald AH, New JP, Worthington J, Ollier WE et al. Polymorphisms in IGF-binding protein 1 are associated with impaired renal function in type 2 diabetes. Diabetes 2005;54:3547-53.
56. Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y. Inhibition of Insulin Receptor Activation by Insulin-like Growth Factor Binding Proteins. J Biol Chemistry 1997;272:30729-34.
57. Maddux BA, Chan A, De Filippis EA, Mandarino LJ, Goldfine ID. IGF-binding protein-1 levels are related to insulin-mediated glucose disposal and are a potential serum marker of insulin resistance. Diabetes Care 2006;29:1535-7.
58. Liew CF, Wise SD, Yeo KP, Lee KO. Insulin-like growth factor binding protein-1 is independently affected by ethnicity, insulin sensitivity, and leptin in healthy, glucose-tolerant young men. J Clin Endocrinol 2005;90:1483-8.
59. Finlay D, Patel S, Dickson LM, Shpiro N, Marquez R, Rhodes CJ et al. Glycogen synthase kinase-3 regulates IGFBP-1 gene transcription through the thymne-rich insulin response element. BMC Molecular Biology 2004;5:15-28.
60. Kalme T, Seppala M, Qiao Q, Koistinen R, Nissinen A, Harrela M et al. Sex Hormone- Binding Protein Globulin and Insulin-like Growth Factor Binding Protein-1 as indicators of metabolic syndrome, cardiovascular risk and mortality in elderly men. J Clin Endocrinol Metab 2005;90:1550-6.
61. O'Byrne SM, Wongsiriroj N, Libien J, Vogel S, Goldberg IJ, Baher W et al. Retinoid absorption and storage is impaired in mice lacking lecithin:retinol acyltransferase (LRAT). J Biol Chem;280:35647-57.
62. Shulman AI, Mangelsdorf DJ. Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 2005;353:604-15.
63. Basualdo CG, Wein EE, Basu TK. Vitamin A (retinol) status of first nation adults with non-insulin-dependent diabetes mellitus. J AmColl Nutr 1997;16:39-45.
64. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR et al. retinol binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med 2006;354:2552-63.
65. Tamori Y, Sakaue H, Kasuga M. RBP4, an unexpected adipokine. Nat Med 2006;12:30-1.
66. Lu J, Dixon WT, Tsin ATC, Basu TK. The metabolic availability of vitamin A is decreased at the onset of diabetes in BB rats. J Nutr 2000;130:1958-62.
67. Janke J, Engeli S, Boschmann M, Adams F, Böhnke J, Luft FC et al. Retinol-binding protein 4 in human obesity. Diabetes 2006;55:2805-10.
68. Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome, Am J Med Sci 2005;330:280-9.
69. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 2005;184:285-93-
70. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update, Clin Endocrinol (Oxf) 2006;64:355-65.
71. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
72. Lowell BB, Susulic VS, Hamann A, Lawitts JA, Himms-Hagen J, Boyer BB et al. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 1993; 366:740-2.
73. Kim DW, Kim BS, Kwon HS, Kim CG, Lee HW, Choi WH et al. Atrophy of brown adipocytes in the adult mouse causes transformation into white adipocyte-like cells. Exp Mol Med 2003;35:518-26.'
74. Hansen E, Hajri T, Abumrad NN. Is all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus. Surgery 2006;139:711-6.
75. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006;95: 136-47.
76. Romanski SA, Nelson RM, Jensen MD. Meal fatty acid uptake in adipose tissue: gender effects in nonobese humans. Am J Physiol Endocrinol Metab 2000;279:E455-E62.
77. Jensen MD. Adipose tissue and fatty acid metabolism in humans. J R Soc Med 2002;95 (Suppl. 42):3-7.
78. Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord 2004;28 (Suppl. 4):S12-S21.
79. Wells JC. The evolution of human fatness and susceptibility to obesity: an ethological approach. Biol Rev Camb Philos Soc 2006;81:183-205.
80. Dulloo AG. Regulation of fat storage via suppressed thermogenesis: a thrifty phenotype that predisposes individuals with catch-up growth to insulin resistance and obesity. Horm Res 2006;65(Suppl. 3):90-7.
81. Holt RI, Byrne CD. Intrauterine growth, the vascular system, and the metabolic syndrome. Semin Vasc Med 2002;2:33-43.
82. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002;25:134-47.
83. Sartor BM, Dickey RP. Polycystic ovarian syndrome and the metabolic syndrome. Am J Med Sci 2005;330:336-42.
84. Simha V, Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 2006;17:162-9.
85. Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative physiology of human adipose tissue. Int J Obes Relat Metab Disord 2003;27:875-88.
86. Karpe F, Tan GD. Adipose tissue function in the insulin-resistance syndrome. Biochem Soc Trans 2005;33:1045-8.
87. Lewis GF, Carpentier A, Adeli K, Giacca A. Disorder fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews 2002;23:201-29-
88. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 2002;51:2951-58.
89. Barzilai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J et al. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999;48:94-8.
90. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007;115:1537-43.
91. Cao H, Maeda K, Gorgun CZ, Kim HJ, Park SY, Shulman GI et al. Regulation of metabolic responses by adipocyte/ macrophage Fatty acid-binding proteins in leptin-deficient mice. Diabetes 2006;55:1915-22.
92. Shum BO, Mackay CR, Gorgun CZ, Frost MJ, Kumar RK, Hotamisligil GS et al. The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. J Clin Invest 2006;116: 2183-92.
93. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-9.
94. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405-13.
95. Kazemi MR, McDonald CM, Shigenaga JK, Grunfeld C, Feingold KR. Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arterioscler Thromb Vasc Biol 2005;25:1220-4.
96. Rakugi H, Kamide K, Ogihara T. Vascular Signaling Pathways in the Metabolic Syndrome. Current Hypertension Reports 2002;4:105-11.
97. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
98. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006;74:443-77.
99. Adeghate E. An update on the biology and physiology of resistin. Cell Mol Life Sci 2004;61:2485-96.
100. Chen MP, Chung FM, Chang DM, Tsai JCR, Huang HF, Shin SJ et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol 2006;91:295-9.
101. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
102. Beltowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 2006;12:RA112-9.
103. Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, Bienkiewicz M et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007;50:1033-7.
104. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146:1764-71.
105. de Sousa Batista CM, Yang RZ, Lee MJ, Glkynn NM, Yu DZ, Pray J et al. Omentin plasma levels and gen expression are decreased in obesity. Diabetes 2007 56:1655-61.
106. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC et al. Identification of omentin as a novel depot specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E 1253-61.
107. Miner JL. The adipocyte as an endocrine cell. J Anim Sci 2004;82:935-41.
108. Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science 1987;237:405-8.
109. Cianflone K, Maslowska M, Sniderman AD. Acilation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin Cell Dev Biol 1999;10:31-41.
110. Saleh J, Christou N, Cianflone K. Regional specificity of ASP binding in human adipose tissue. Endocrinol Metab 1999; 39:E815-21.
111. Zorad S, Fickova M, Zelezna B, Macho L, Kral JG. The role of angiotensin II and its receptors in regulation of adipose tissue metabolism and cellularity. Gen Physiol Biophys 1995;14:383-91.
112. Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint-Marc P, Teboul M. Angiotensinogen, angiotensin II and adipose tissue development. Int J Obes Relat Metab Disord 2000;24:S33-5.
113. Massiéra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gase JM et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001;15:2727-9.
114. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 2000;24:S23-7.
115. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor Necrosis Factor-· suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes Nuclear Factor-ÎB activation by TNF-· is obligatory. Proc Natl Acad Sci U S A 2000;97:8033-8.
116. Xing H, Northrop JP, Grove JR, Kilpatrick KE, Su JL, Ringold GM. TNF alpha-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARgamma without effects on Pref-1 expression. Endocrinology 1997;138:2776-83.
117. Stejskal D, Adamovská S, Bartek J, Juráková R, Prosková J. Resistin-concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147:63-9.
118. Nisoli E, Briscini L, Giordano A, Tonello C, Wiesbrock SM, Uysal KT et al. Tumor necrosis factor alpha mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity. Proc Natl Acad Sci U S A 2000;97:8033-8.
119. Dunger A, Cunningham JM, Delaney CA, Lowe JE, Green MH, Bone AJ et al. Tumor necrosis factor-alpha and interferon-gamma inhibit insulin secretion and cause DNA damage in unweaned-rat islets. Extent of nitric oxide involvement. Diabetes 1996;45:183-9.
120. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2003;52:1799-805.
121. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14.
122. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J et al.Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003;301:1045-50.
123. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
124. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-30.
125. Murdolo G, Smith U. The disregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutr Metab Cardiovasc Dis 2006;16:S35-S8.
126. Guzik TJ, Mangalat D, Korbut R. Adipokines-novel link between inflammation and vascular function? J Phys Pharmacol 2006;57:505-28.